BACKGROUND: Annual influenza vaccination is routinely recommended for pediatric solid organ transplant recipients. However, there are limited data defining the immune response to the inactivated vaccine in this population. METHODS: This prospective study compared the humoral and cell-mediated immune responses to the trivalent subvirion influenza vaccine in pediatric liver transplant recipients with those in their healthy siblings. All subjects received inactivated influenza vaccine. Hemagglutination inhibition and interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot assays for New Caledonia and Shanghai strains were performed at baseline, after each vaccine dose, and 3 months after the series. Seroconversion was defined as a 4-fold increase in antibody titers; seroprotection was defined as an antibody titer > or =1:40. An increase in the number of T cells secreting IFN-gamma was considered to be a positive enzyme-linked immunosorbent spot response. RESULTS: After 1 dose of vaccine, transplant recipients achieved rates of antibody seroprotection and seroconversion that were similar to those achieved by their healthy siblings. However, for both influenza strains, IFN-gamma responses by enzyme-linked immunosorbent spot were significantly attenuated in transplant recipients after 2 doses of vaccine. No cases of influenza or vaccine-related serious adverse events were documented in the study. CONCLUSIONS: The diminished cell-mediated immune response to influenza vaccination that was observed in pediatric liver transplant recipients suggests that the current vaccine strategy may not provide optimal protection. Because of concerns regarding potential emergence of more virulent influenza strains, further studies are warranted to determine if IFN-gamma responses are predictive of efficacy and to identify the optimal vaccination strategy to protect populations with a high risk of infection.
BACKGROUND: Annual influenza vaccination is routinely recommended for pediatric solid organ transplant recipients. However, there are limited data defining the immune response to the inactivated vaccine in this population. METHODS: This prospective study compared the humoral and cell-mediated immune responses to the trivalent subvirion influenza vaccine in pediatric liver transplant recipients with those in their healthy siblings. All subjects received inactivated influenza vaccine. Hemagglutination inhibition and interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot assays for New Caledonia and Shanghai strains were performed at baseline, after each vaccine dose, and 3 months after the series. Seroconversion was defined as a 4-fold increase in antibody titers; seroprotection was defined as an antibody titer > or =1:40. An increase in the number of T cells secreting IFN-gamma was considered to be a positive enzyme-linked immunosorbent spot response. RESULTS: After 1 dose of vaccine, transplant recipients achieved rates of antibody seroprotection and seroconversion that were similar to those achieved by their healthy siblings. However, for both influenza strains, IFN-gamma responses by enzyme-linked immunosorbent spot were significantly attenuated in transplant recipients after 2 doses of vaccine. No cases of influenza or vaccine-related serious adverse events were documented in the study. CONCLUSIONS: The diminished cell-mediated immune response to influenza vaccination that was observed in pediatric liver transplant recipients suggests that the current vaccine strategy may not provide optimal protection. Because of concerns regarding potential emergence of more virulent influenza strains, further studies are warranted to determine if IFN-gamma responses are predictive of efficacy and to identify the optimal vaccination strategy to protect populations with a high risk of infection.
Authors: Marie Paule Kieny; Alejandro Costa; Joachim Hombach; Peter Carrasco; Yuri Pervikov; David Salisbury; Michel Greco; Ian Gust; Marc LaForce; Carlos Franco-Paredes; José Ignacio Santos; Eric D'Hondt; Guus Rimmelzwaan; Ruth Karron; Keiji Fukuda Journal: Vaccine Date: 2006-09-29 Impact factor: 3.641
Authors: Robert L Atmar; Wendy A Keitel; Thomas R Cate; Flor M Munoz; Fred Ruben; Robert B Couch Journal: Vaccine Date: 2007-05-22 Impact factor: 3.641
Authors: David van Duin; Heather G Allore; Subhasis Mohanty; Sandra Ginter; Frances K Newman; Robert B Belshe; Ruslan Medzhitov; Albert C Shaw Journal: J Infect Dis Date: 2007-04-17 Impact factor: 5.226
Authors: Y Miyahira; K Murata; D Rodriguez; J R Rodriguez; M Esteban; M M Rodrigues; F Zavala Journal: J Immunol Methods Date: 1995-04-12 Impact factor: 2.303
Authors: Amy G Feldman; Brenda L Beaty; Donna Curtis; Elizabeth Juarez-Colunga; Allison Kempe Journal: JAMA Pediatr Date: 2019-03-01 Impact factor: 16.193
Authors: Mariangela R Resende; Shahid Husain; Jonathan Gubbay; Lianne Singer; Edward Cole; Eberhard L Renner; Coleman Rotstein Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471
Authors: Karen L Kotloff; Natasha B Halasa; Christopher J Harrison; Janet A Englund; Emmanuel B Walter; James C King; C Buddy Creech; Sara A Healy; Rowena J Dolor; Ina Stephens; Kathryn M Edwards; Diana L Noah; Heather Hill; Mark Wolff Journal: Pediatr Infect Dis J Date: 2014-08 Impact factor: 2.129
Authors: Charles R Beck; Bruce C McKenzie; Ahmed B Hashim; Rebecca C Harris; Arina Zanuzdana; Gabriel Agboado; Elizabeth Orton; Laura Béchard-Evans; Gemma Morgan; Charlotte Stevenson; Rachel Weston; Mitsuru Mukaigawara; Joanne Enstone; Glenda Augustine; Mobasher Butt; Sophie Kim; Richard Puleston; Girija Dabke; Robert Howard; Julie O'Boyle; Mary O'Brien; Lauren Ahyow; Helene Denness; Siobhan Farmer; Jose Figureroa; Paul Fisher; Felix Greaves; Munib Haroon; Sophie Haroon; Caroline Hird; Rachel Isba; David A Ishola; Marko Kerac; Vivienne Parish; Jonathan Roberts; Julia Rosser; Sarah Theaker; Dean Wallace; Neil Wigglesworth; Liz Lingard; Yana Vinogradova; Hiroshi Horiuchi; Javier Peñalver; Jonathan S Nguyen-Van-Tam Journal: PLoS One Date: 2011-12-22 Impact factor: 3.240